Skip to content
Bending the Curve Trial by Trial
?

Back to Colorectal cancer

References: Colorectal cancer

191 sources cited on this page. Links open the primary source.

  1. Ernest Miles W. A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon. The Lancet. 1908;172(4451):1812-1813. DOI
    CiteLoading…
  2. Dukes CE. The classification of cancer of the rectum. The Journal of Pathology and Bacteriology. 1932;35(3):323-332. DOI
    CiteLoading…
  3. HEIDELBERGER C, CHAUDHURI NK, DANNEBERG P, MOOREN D, GRIESBACH L, DUSCHINSKY R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663-6. PubMedDOI
    CiteLoading…
  4. U.S. Food and Drug Administration. Drugs@FDA data via openFDA, application NDA012209 (fluorouracil), submission ORIG 1 status date 1962-04-25. Indication text not read. Source
  5. Lynch HT, Krush AJ. Cancer family "G" revisited: 1895-1970. Cancer. 1971;27(6):1505-11. PubMedDOI
    CiteLoading…
  6. Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974;67(6 Pt 1):451-7. PubMed
    CiteLoading…
  7. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?. Br J Surg. 1982;69(10):613-6. PubMedDOI
    CiteLoading…
  8. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479-82. PubMedDOI
    CiteLoading…
  9. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2(8514):996-9. PubMedDOI
    CiteLoading…
  10. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1(8545):1303-6. PubMedDOI
    CiteLoading…
  11. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-32. PubMedDOI
    CiteLoading…
  12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67. PubMedDOI
    CiteLoading…
  13. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352-8. PubMedDOI
    CiteLoading…
  14. U.S. Food and Drug Administration. Drugs@FDA data via openFDA, application NDA020035 (Ergamisol, levamisole), submission ORIG 1 status date 1990-06-18. Indication text not read. Source
  15. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260(5109):812-6. PubMedDOI
    CiteLoading…
  16. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75(5):1027-38. PubMedDOI
    CiteLoading…
  17. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75(6):1215-25. PubMedDOI
    CiteLoading…
  18. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365-71. PubMedDOI
    CiteLoading…
  19. Peltomäki P, Aaltonen LA, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993;260(5109):810-2. PubMedDOI
    CiteLoading…
  20. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816-9. PubMedDOI
    CiteLoading…
  21. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977-81. PubMedDOI
    CiteLoading…
  22. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994;368(6468):258-61. PubMedDOI
    CiteLoading…
  23. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321-6. PubMedDOI
    CiteLoading…
  24. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-7. PubMedDOI
    CiteLoading…
  25. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-71. PubMedDOI
    CiteLoading…
  26. Swedish Rectal Cancer Trial, Cedermark B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE, Wilking N. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980-7. PubMedDOI
    CiteLoading…
  27. US Food and Drug Administration. Supplement approval letter, Camptosar (irinotecan hydrochloride injection), NDA 20-571/S-008, Pharmacia & Upjohn; letter dated 22 October 1998 (date stamp on the scanned letter; the letter also gives 22 October 1998 as the user-fee goal date). Source
  28. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-47. PubMedDOI
    CiteLoading…
  29. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-7. PubMedDOI
    CiteLoading…
  30. US Food and Drug Administration. Supplement approval letter, Camptosar (irinotecan hydrochloride injection), NDA 20-571/S-009, Pharmacia & Upjohn; letter dated 20 April 2000. Source
  31. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136-47. PubMedDOI
    CiteLoading…
  32. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905-14. PubMedDOI
    CiteLoading…
  33. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-46. PubMedDOI
    CiteLoading…
  34. US Food and Drug Administration. Approval letter, Eloxatin (oxaliplatin) for Injection, NDA 21-492, Sanofi-Synthelabo, Inc.; electronically signed 9 August 2002. Source
  35. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-8. PubMedDOI
    CiteLoading…
  36. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003;21(1):3-7. PubMedDOI
    CiteLoading…
  37. Wiley MJ, Rieger N. Audit and the birth of the abdomino-perineal excision for carcinoma of the rectum. ANZ J Surg. 2003;73(10):858-61. PubMedDOI
    CiteLoading…
  38. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-51. PubMedDOI
    CiteLoading…
  39. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-45. PubMedDOI
    CiteLoading…
  40. US Food and Drug Administration. Approval letter, Avastin (bevacizumab), STN BL 125085/0, Genentech, Incorporated; letter dated 26 February 2004 (scanned document, read by optical character recognition). Source
  41. U.S. Food and Drug Administration. Supplement approval letter, NDA 21-492/S-004 and S-005, Eloxatin (oxaliplatin). Signed 4 November 2004. Source
  42. US Food and Drug Administration. Supplement approval letter, Eloxatin (oxaliplatin) for Injection, NDA 21-492/S-002, Sanofi-Synthelabo, Inc.; electronically signed 9 January 2004. Source
  43. US Food and Drug Administration. Biologics licence letter, Erbitux (cetuximab), STN BL 125084/0, ImClone Systems, Incorporated; letter dated 12 February 2004 (scanned document, read by optical character recognition). Source
  44. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711-7; discussion 717-8. PubMedDOI
    CiteLoading…
  45. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42. PubMedDOI
    CiteLoading…
  46. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40. PubMedDOI
    CiteLoading…
  47. Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA. 2005;294(17):2195-202. PubMedDOI
    CiteLoading…
  48. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644-50. PubMedDOI
    CiteLoading…
  49. US Food and Drug Administration. Biologics licence letter, Vectibix (panitumumab), STN BL 125147/0, Amgen, Incorporated; letter dated 27 September 2006. Source
  50. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5. PubMedDOI
    CiteLoading…
  51. US Food and Drug Administration. Supplement approval letter, Erbitux (cetuximab), STN BL 125084/103, ImClone Systems, Incorporated; letter dated 2 October 2007 (scanned document, read by optical character recognition). Source
  52. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040-8. PubMedDOI
    CiteLoading…
  53. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-204. PubMedDOI
    CiteLoading…
  54. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693-701. PubMedDOI
    CiteLoading…
  55. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-64. PubMedDOI
    CiteLoading…
  56. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34. PubMedDOI
    CiteLoading…
  57. US Food and Drug Administration. Supplement approval letter, Vectibix (panitumumab), STN BL 125147/26, Amgen, Incorporated; letter dated 23 June 2008. The letter restates the accelerated-approval (Subpart E) status of the 27 September 2006 approval. Source
  58. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783-8. PubMedDOI
    CiteLoading…
  59. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65. PubMedDOI
    CiteLoading…
  60. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-16. PubMedDOI
    CiteLoading…
  61. US Food and Drug Administration. Supplement approval letter, Erbitux (cetuximab), STN BL 125084/167, ImClone Systems, Incorporated; labeling revision on lack of efficacy in KRAS-mutated colorectal cancer. The copy read carries no date line; the Drugs@FDA history page lists this supplement on 07/17/2009. Source
  62. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17. PubMedDOI
    CiteLoading…
  63. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-33. PubMedDOI
    CiteLoading…
  64. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11-6. PubMedDOI
    CiteLoading…
  65. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479-507. PubMedDOI
    CiteLoading…
  66. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310-22. PubMedDOI
    CiteLoading…
  67. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82. PubMedDOI
    CiteLoading…
  68. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383-93. PubMedDOI
    CiteLoading…
  69. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225-33. PubMedDOI
    CiteLoading…
  70. US Food and Drug Administration. Supplement approval letter, Erbitux (cetuximab), BLA 125084/225, ImClone LLC; electronically signed 6 July 2012. Subpart E fulfilment and K-ras mutation-negative indication. Source
  71. US Food and Drug Administration. NDA approval letter, Stivarga (regorafenib) tablets, NDA 203085, Bayer HealthCare Pharmaceuticals, Inc.; electronically signed 27 September 2012. Source
  72. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-33. PubMedDOI
    CiteLoading…
  73. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-57. PubMedDOI
    CiteLoading…
  74. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61(7):1036-40. PubMedDOI
    CiteLoading…
  75. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687-96. PubMedDOI
    CiteLoading…
  76. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12. PubMedDOI
    CiteLoading…
  77. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106-14. PubMedDOI
    CiteLoading…
  78. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606-15. PubMedDOI
    CiteLoading…
  79. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862-73. PubMedDOI
    CiteLoading…
  80. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176-87. PubMedDOI
    CiteLoading…
  81. US Food and Drug Administration. NDA approval letter, Lonsurf (trifluridine and tipiracil) tablets, NDA 207981, Taiho Oncology, Inc.; electronically signed 22 September 2015. Source
  82. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20. PubMedDOI
    CiteLoading…
  83. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15(3):181-94. PubMedDOI
    CiteLoading…
  84. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-19. PubMedDOI
    CiteLoading…
  85. Lirici MM, Hüscher CG. Techniques and technology evolution of rectal cancer surgery: a history of more than a hundred years. Minim Invasive Ther Allied Technol. 2016;25(5):226-33. PubMedDOI
    CiteLoading…
  86. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738-746. PubMedDOI
    CiteLoading…
  87. Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299-1311. PubMedDOI
    CiteLoading…
  88. US Food and Drug Administration. Accelerated approval letter, Opdivo (nivolumab), BLA 125554/S-034, Bristol-Myers Squibb Company; electronically signed 31 July 2017. Source
  89. US Food and Drug Administration. Approval letter, BLA 125514/S-14, Keytruda (pembrolizumab), Merck Sharp and Dohme Corp.; electronically signed 23 May 2017. Source
  90. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191. PubMedDOI
    CiteLoading…
  91. André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, et al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol. 2018;36(15):1469-1477. PubMedDOI
    CiteLoading…
  92. US Food and Drug Administration. Accelerated approval letter, Opdivo (nivolumab) with ipilimumab, BLA 125554/S-063, Bristol-Myers Squibb Company; electronically signed 10 July 2018. Source
  93. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018;378(13):1177-1188. PubMedDOI
    CiteLoading…
  94. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, et al. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Ann Intern Med. 2018;168(11):775-782. PubMedDOI
    CiteLoading…
  95. Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018;19(4):562-578. PubMedDOI
    CiteLoading…
  96. Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496. PubMedDOI
    CiteLoading…
  97. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779. PubMedDOI
    CiteLoading…
  98. Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, et al. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. J Clin Oncol. 2018;36(15):1478-1485. PubMedDOI
    CiteLoading…
  99. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537-2545. PubMedDOI
    CiteLoading…
  100. Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. PubMedDOI
  101. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643. PubMedDOI
    CiteLoading…
  102. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518-530. PubMedDOI
    CiteLoading…
  103. Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, et al. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Ann Oncol. 2019;30(8):1304-1310. PubMedDOI
    CiteLoading…
  104. Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, et al. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019;5(11):1574-1581. PubMedDOI
    CiteLoading…
  105. André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21(12):1620-1629. PubMedDOI
    CiteLoading…
  106. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. PubMedDOI
    CiteLoading…
  107. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-1305. PubMedDOI
  108. US Food and Drug Administration. Supplement approval letter, Braftovi (encorafenib) capsules, NDA 210496/S-006, Array BioPharma, Inc.; electronically signed 8 April 2020. Source
  109. US Food and Drug Administration. Supplement approval letter, Keytruda (pembrolizumab), BLA 125514/S-084, Merck Sharp & Dohme Corp.; electronically signed 29 June 2020. Source
  110. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29-42. PubMedDOI
    CiteLoading…
  111. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329-359. PubMedDOI
  112. Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702-715. PubMedDOI
    CiteLoading…
  113. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PubMedDOI
  114. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256-266. PubMedDOI
    CiteLoading…
  115. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779-789. PubMedDOI
    CiteLoading…
  116. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273-284. PubMedDOI
    CiteLoading…
  117. Bretthauer M, Løberg M, Wieszczy P, Kalager M, Emilsson L, Garborg K, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. N Engl J Med. 2022;387(17):1547-1556. PubMedDOI
    CiteLoading…
  118. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-2376. PubMedDOI
    CiteLoading…
  119. Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659-670. PubMedDOI
    CiteLoading…
  120. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546-2556. PubMedDOI
    CiteLoading…
  121. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022;40(15):1681-1692. PubMedDOI
    CiteLoading…
  122. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40(2):161-170. PubMedDOI
    CiteLoading…
  123. Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386(24):2261-2272. PubMedDOI
    CiteLoading…
  124. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, et al. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023;41(21):3724-3734. PubMedDOI
    CiteLoading…
  125. Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. PubMedDOI
  126. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53. PubMedDOI
    CiteLoading…
  127. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766-e772. PubMedDOI
    CiteLoading…
  128. Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389(23):2125-2139. PubMedDOI
    CiteLoading…
  129. US Food and Drug Administration. NDA approval letter, Fruzaqla (fruquintinib), NDA 217564, Takeda Pharmaceuticals USA, Inc.; electronically signed 8 November 2023. Source
  130. US Food and Drug Administration. Supplement approval letter, Lonsurf (trifluridine/tipiracil), NDA 207981/S-012, Taiho Oncology, Inc.; electronically signed 2 August 2023. Source
  131. US Food and Drug Administration. Accelerated approval letter, Tukysa (tucatinib) tablets, NDA 213411/S-004, Seagen Inc.; electronically signed 19 January 2023. Source
  132. Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol. 2023;41(8):1541-1552. PubMedDOI
    CiteLoading…
  133. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023;388(18):1657-1667. PubMedDOI
    CiteLoading…
  134. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322-334. PubMedDOI
    CiteLoading…
  135. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496-508. PubMedDOI
    CiteLoading…
  136. Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388(1):44-54. PubMedDOI
    CiteLoading…
  137. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, et al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024;391(21):2014-2026. PubMedDOI
    CiteLoading…
  138. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(2 D). PubMedDOI
  139. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(6):366-375. PubMedDOI
  140. Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024;390(21):1949-1958. PubMedDOI
    CiteLoading…
  141. Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):873-881. PubMedDOI
    CiteLoading…
  142. Green K. Dukes' classification. EBSCO Research Starters, Health and Medicine, 2024. Accessed 20 October 2026. Source
  143. European Medicines Agency. Lonsurf (trifluridine/tipiracil): European public assessment report page; marketing authorisation issued 25 April 2016; page last updated 5 April 2024. Source
  144. US Food and Drug Administration. Accelerated approval letter, Braftovi (encorafenib) capsules, NDA 210496/S-017, Array BioPharma Inc.; electronically signed 20 December 2024. Source
  145. US Food and Drug Administration. Accelerated approval letter, Enhertu (fam-trastuzumab deruxtecan-nxki), BLA 761139/S-028, Daiichi Sankyo, Inc.; electronically signed 5 April 2024. Source
  146. US Food and Drug Administration. Accelerated approval letter, Krazati (adagrasib) tablet, NDA 216340/S-005, Mirati Therapeutics, Inc.; electronically signed 21 June 2024. Source
  147. Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42(5):500-506. PubMedDOI
    CiteLoading…
  148. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36(3):277-284. PubMedDOI
    CiteLoading…
  149. André T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383-395. PubMedDOI
    CiteLoading…
  150. Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025;392(23):2297-2308. PubMedDOI
    CiteLoading…
  151. Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N Engl J Med. 2025;392(24):2425-2437. PubMedDOI
    CiteLoading…
  152. US Food and Drug Administration. Supplement approval letter (corrected), Lumakras (sotorasib) tablets, NDA 214665/S-009, Amgen Inc.; electronically signed 16 January 2025. Source
  153. US Food and Drug Administration. Supplement approval and fulfilment of postmarketing requirement letter, Opdivo (nivolumab), BLA 125554/S-132, Bristol-Myers Squibb Company; electronically signed 8 April 2025. Source
  154. Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets-Tan R, et al. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(9):1007-1024. PubMedDOI
  155. Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31(3):901-908. PubMedDOI
    CiteLoading…
  156. Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. J Clin Oncol. 2025;43(19):2147-2154. PubMedDOI
    CiteLoading…
  157. Sakai Y. Revisiting Japanese contributions to abdomino-perineal resection for rectal cancer. Surg Today. 2025;55(6):857-859. PubMedDOI
    CiteLoading…
  158. Seligmann JF, Morton D, Elliott F, Handley K, Gray R, Seymour M, et al. Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population. Ann Oncol. 2025;36(5):520-528. PubMedDOI
    CiteLoading…
  159. Shi J, Løberg M, Kalager M, Wieszczy P, Pilonis ND, Adami HO, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death: instrumental variable estimation of per-protocol effects. Eur J Epidemiol. 2025;40(4):419-425. PubMedDOI
    CiteLoading…
  160. Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509-1518. PubMedDOI
    CiteLoading…
  161. Tie J, Wang Y, Loree JM, Cohen JD, Wong R, Price T, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nat Med. 2025;31(12):4291-4300. PubMedDOI
    CiteLoading…
  162. Cremolini C, Chalabi M, Elez E, Fassan M, Gelli M, Goéré D, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(6):759-776. PubMedDOI
  163. Cancer Research UK. Bowel cancer survival statistics. Health professional page, read from the page HTML. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival. Page accessed 20 October 2026; no update date seen. Source
  164. ClinicalTrials.gov. NCT00883792 (NordICC). Registry record, accessed 20 October 2026. NCT00883792
  165. ClinicalTrials.gov. NCT02997228 (COMMIT, NRG-GI004/S1610). Registry record, API v2, accessed 20 October 2026. NCT02997228
  166. ClinicalTrials.gov. NCT04120701 (CIRCULATE, PRODIGE 70). Registry record, API v2, accessed 20 October 2026. NCT04120701
  167. ClinicalTrials.gov. NCT04246684 (ACO/ARO/AIO-18.1). Registry record, API v2, accessed 20 October 2026. NCT04246684
  168. ClinicalTrials.gov. NCT04793958 (KRYSTAL-10). Registry record (last update posted 28 September 2026; no results posted), accessed 20 October 2026. NCT04793958
  169. ClinicalTrials.gov. NCT05253651 (MOUNTAINEER-03). Registry record, API v2, accessed 20 October 2026. NCT05253651
  170. ClinicalTrials.gov. NCT05855200 (AZUR-2). Registry record, API v2, accessed 20 October 2026. NCT05855200
  171. ClinicalTrials.gov. NCT06997497 (KANDLELIT-012, MK-1084-012). Registry record, API v2, accessed 20 October 2026. NCT06997497
  172. European Medicines Agency. Braftovi: EPAR overview and product information (indications section). Page accessed 20 October 2026; the page shows a last-updated date of 22/07/2026 and several per-document dates. Source
  173. European Medicines Agency. Fruzaqla (fruquintinib): European public assessment report page; marketing authorisation issued 20 June 2024; page last updated 21 September 2026. Source
  174. European Medicines Agency. Keytruda: EPAR overview and product information (indications section). Page accessed 20 October 2026; the page shows several per-document last-updated dates in 2026. Source
  175. European Medicines Agency. Opdivo (nivolumab): European public assessment report page. Fetched 20 October 2026. Source
  176. European Medicines Agency. Stivarga (regorafenib): European public assessment report page; marketing authorisation issued 26 August 2013; page last updated 24 March 2026. Source
  177. Exelixis, Inc. Form 8-K dated 10 September 2026 (SEC EDGAR): FDA extension of the review period for the zanzalintinib NDA. Company filing; accessed 20 October 2026. Source
  178. US Food and Drug Administration. Supplement approval and fulfilment of postmarketing requirement letter, Braftovi (encorafenib) capsules, NDA 210496/S-019, Array BioPharma Inc.; electronically signed 24 February 2026. Source
  179. US Food and Drug Administration. Drugs@FDA: approval date(s) and history, letters, labels, reviews for BLA 125084 (Erbitux, cetuximab). Page read 20 October 2026; lists ORIG-1 on 02/12/2004, SUPPL-103 on 10/02/2007 and SUPPL-167 on 07/17/2009. Source
  180. US Food and Drug Administration. Supplement approval and fulfilment of postmarketing requirement letter (voluntary withdrawal of the accelerated-approval colorectal indication), Krazati (adagrasib) tablet, NDA 216340/S-011, Bristol-Myers Squibb Company; electronically signed 1 September 2026. Source
  181. U.S. Food and Drug Administration. Supplement approval letter, BLA 761034/S-065, Tecentriq (atezolizumab). Signed 8 October 2026. Source
  182. GSK plc. Jemperli (dostarlimab-gxly) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer. Stock-exchange announcement, Philadelphia, PA, 24 August 2026. Source
  183. Iveson T, Saunders MP, Kelly C, Kerr RS, Cassidy J, Hollander NH, et al. Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial. J Clin Oncol. 2026;44(7):534-539. PubMedDOI
    CiteLoading…
  184. OncLive. FDA extends review period for zanzalintinib plus atezolizumab NDA in pretreated metastatic colorectal cancer. News article published 11 September 2026; accessed 20 October 2026. Secondary source: the company or FDA document was not read. Source
  185. US Food and Drug Administration. openFDA device PMA API records for P130017 (Cologuard, Exact Sciences Corporation): original PMA decision and supplements. Queried 20 October 2026. Source
  186. US Food and Drug Administration. openFDA device PMA API records for P230009 (Shield, Guardant Health, Inc.): original PMA decision and supplements. Queried 20 October 2026. Source
  187. Pentheroudakis G, Argilés G, Arnold D, Smyth E, Ducreux M. ESMO Clinical Practice Guideline Express Update on the adoption of physical exercise in patients with localised colon cancer. ESMO Open. 2026;11(2):106019. PubMedDOI
  188. Sagawa T, Nagashima H, Fujikawa K. KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions. J Gastrointest Cancer. 2026;57(1). PubMedDOI
    CiteLoading…
  189. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Colorectal Cancer. Page accessed 20 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Source
  190. Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026;394(12):1155-1166. PubMedDOI
    CiteLoading…
  191. Wolf AMD, Hoffman RM, Walter LC, Zeigler-Johnson C, Church TR, Guerra CE, et al. Colorectal cancer screening: An update to the American Cancer Society guideline, 2026. CA Cancer J Clin. 2026;76(3):e70083. PubMedDOI
    CiteLoading…